Tokyo, August 25, 2015 -- Moody's Japan K.K. says that Japan's five-largest pharmaceutical companies by revenue will see revenue contributions from the Japanese market contract over the next five years because of the increasing use of generic drugs in the country.

Vollständigen Artikel bei Moodys lesen